Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Table 3 Pathologic characteristics of the operative specimen from patients (N = 110^a)

	Arm A		Arm B		Total		P value
	No.	%	No.	%	No.	%	P value
Type of surgery
Miles	36	67.90%	32	56.10%	68	61.80%
Anterior resection	13	24.50%	22	38.60%	35	31.80%
Hartmann	4	7.50%	3	5.30%	7	6.40%	0.279
ypT stage
ypT0	10	18.90%	16	28.10%	26	23.60%
ypT1–2	16	30.20%	24	42.10%	40	36.40%
ypT3–4	27	50.90%	17	29.80%	44	40.00%	0.077
ypN stage
N0	29	54.70%	39	68.40%	68	61.80%
N+	24	45.30%	18	31.60%	42	38.20%	0.139
pCR
pCR	8	15.10%	14	24.60%	22	20.00%
non-pCR	45	84.90%	43	75.40%	88	80.00%	0.215
Total	53		57		110

Arm A, 5 weeks of treatment with radiotherapy 50 Gy/25 fractions with concurrent capecitabine 625 mg/m² twice daily 5 days per week and oxaliplatin 50 mg/m² once weekly; Arm B, 5 weeks of treatment with radiotherapy 55 Gy/25 fractions with concurrent capecitabine 625 mg/m² twice daily 5 days per week and oxaliplatin 50 mg/m² once weekly, followed by a cycle of XELOX
Abbreviations: pCR Pathological complete response;^aPatients who did not undergo surgery excluded

ISSN: 1748-717X